Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy2 차 항체 결핍 환자의 지속적인 SARS-COV-2 감염 : Casirivimab 및 Imdevimab (Regn-Cov2) 모노클로 날 항체 요법에 따른 성공적인 통관Case Reports Published on 2021-12-302022-09-01 Journal: Annals of Clinical Microbiology and Antimicrobials [Category] SARS, 변종, 진단, 치료기술, [키워드] accompanied administration antibody Antibody deficiency Antibody Response Antibody responses antiviral therapy B cell B cell depleting therapy benefit Case report case reports Casirivimab Chronic COVID-19 Chronic lymphocytic leukaemia clearance Clinical improvement clinical recovery clinical response clinical study Clinical use Combination convalescent plasma deficiency delivery depleting ecological ecological niche Effectiveness evade Evidence Evolution failure fatigue female follicular Follicular lymphoma Formal highlight hospitalised Ibrutinib Imdevimab immune evasion Immunotherapy increased risk individuals Infection Inflammation lack lymphoma malaise male monoclonal antibody monoclonal antibody combination nasopharyngeal swabs neutralisation omicron outcome Passive immunisation Patient patients persistent persistent infection Primary and secondary immunodeficiency raised REGN-CoV2 Remdesivir Ronapreve (REGN-COV2) SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants secondary antibody secure Sequence analysis spike variant suffered sustained therapeutic therapy treated Treatment variants variants of concern Viral viral clearance viral evolution virological clearance with COVID-19 withdrawn [DOI] 10.1186/s12941-021-00491-2 PMC 바로가기 [Article Type] Case Reports
Passive immune therapies: another tool against COVID-19수동 면역 요법: COVID-19에 대한 또 다른 도구Review Published on 2021-12-102022-09-11 Journal: Hematology. American Society of Hematology. Educat [Category] SARS, 진단, 치료제, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval benefit Casirivimab convalescent plasma coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Emergency use Evidence fatal COVID-19 Globulin high risk hyperimmune hyperimmune globulin immune immune system Infection Japan lack Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal neutralizing monoclonal antibodies other treatment pandemic Passive Patient patient groups performed Prevent Regulatory required Research respiratory respiratory infections SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe respiratory infections Therapies therapy treat Treatment United Kingdom [DOI] 10.1182/hematology.2021000299 PMC 바로가기 [Article Type] Review
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19COVID-19 외래 환자의 REGEN-COV 항체 조합 및 결과Clinical Trial Published on 2021-12-022022-09-11 Journal: The New England Journal of Medicine [Category] 변종, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive adverse event Analysis assigned baseline Casirivimab Combination Comparisons coronavirus coronavirus disease Coronavirus disease 2019 death dose end point End points evaluated faster GRADE groups Hierarchical Hospitalization Imdevimab in viral in vitro infusion intravenous less log mean difference median time monoclonal antibodies monoclonal antibody occurred outcome Outpatient outpatients Patient Phase 3 Placebo placebo group portion randomization Randomly reaction receive reduced REGEN-COV Regeneron Pharmaceutical Regeneron Pharmaceuticals Relative risk resolution of symptom resolution of symptoms resolved respiratory risk risk factor Risk factors risk reduction Safety SARS-CoV-2 SARS-CoV-2 viral load Serious Adverse Events serum serum antibody severe disease subgroups Symptom the patient the placebo group the SARS-CoV-2 Trial variants of concern Viral Viral load was used [DOI] 10.1056/NEJMoa2108163 PMC 바로가기 [Article Type] Clinical Trial
Real world utilization of REGEN-COV2 at a community hospital지역 병원에서 REGEN-COV2의 실제 활용Article Published on 2021-12-012022-09-11 Journal: The American journal of emergency medicine [Category] 진단, 치료제, [키워드] Adult patients age allergic reaction Allergic reactions antibody authorization Casirivimab Community community hospital coronavirus disease Coronavirus disease 2019 COVID-19 decrease demographics determine drug Drug administration Emergency emergency department Emergency use authorization EUA female food greater healthcare hospital Hospital mortality Hospitalization hospitalizations Hospitalized Imdevimab in-hospital mortality infused infusion IQR median median age median time Mild mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 monoclonal antibodies monoclonal antibody Patient REGN-CoV2 Seven shown study period suffered the median treated Treatment Viral Viral load were given [DOI] 10.1016/j.ajem.2021.07.050 PMC 바로가기 [Article Type] Article
Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surgeSARS-CoV-2 B1.617.2(델타) 급증 중 획기적인 COVID-19 및 카시리비맙-임데비맙 치료Article Published on 2021-12-012022-09-11 Journal: Journal of Clinical Virology [Category] MERS, SARS, 변종, 진단, 치료법, [키워드] 95% confidence interval Casirivimab Clinical outcome cohorts Comorbidities COVID-19 COVID-19 case Delta delta variant eligible enrolled high-risk patient Hospitalization Imdevimab individuals majority monoclonal antibody monoclonal antibody treatment occurred outcomes Patient patients with COVID-19 Ratio receive SARS-CoV-2 significantly lower study period treated Treatment untreated patients vaccinated individual vaccinated individuals vaccination [DOI] 10.1016/j.jcv.2021.105026 PMC 바로가기 [Article Type] Article
Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccinesSARS-CoV-2 스파이크 단백질 중화 항체 탈출: 항체 기반 Covid-19 치료제 및 백신에 대한 위험 평가Review Published on 2021-11-012022-09-11 Journal: Reviews in Medical Virology [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] Affect African antibody B.1.1.7 B.1.351 bamlanivimab BNT162b2 Casirivimab circulating clades Combination convalescent convalescent plasma convergent evolution COVID-19 Deletion E484K Efficacy etesevimab focus hotspot Imdevimab immune Immune escape immunoglobulins inventory L452R LY-CoV555 LyCoV016 monoclonal antibodies mRNA mRNA-1273 Mutation mutations N439K N501Y neutralising neutralising antibody P.1 P.2 Phylogenetic polyclonal polyclonal immunoglobulins. Protein RBD Receptor binding domain REGN10933 REGN10987 Risk assessment S477N SARS-CoV-2 SARS-CoV-2 spike serum South spike Spike protein Strains target Therapeutics Vaccine Vaccines variants of concern Y453F [DOI] 10.1002/rmv.2231 PMC 바로가기 [Article Type] Review
Casirivimab/Imdevimab: First Approval카시리비맙/임데비맙: 최초 승인Review Published on 2021-11-012022-09-11 Journal: Drugs [Category] SARS, 신약개발, 진단, [키워드] acute COVID-19 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval Canada Casirivimab causative agent Combination coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 treatment eligibility Emergency use authorization Human monoclonal antibody IgG1 Imdevimab Immunoglobulin India Infection Japan Mild Moderate COVID-19 Neutralizing positive Prophylaxis respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus Spike protein Switzerland the spike protein Treatment treatment of COVID-19 USA [DOI] 10.1007/s40265-021-01620-z PMC 바로가기 [Article Type] Review
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 20192019년 경증에서 중등도의 코로나바이러스 질환 고위험 환자 중 밤라니비맙과 카시리비맙-임데비맙의 실제 임상 결과Observational Study Published on 2021-10-282022-09-12 Journal: The Journal of Infectious Diseases [Category] MERS, SARS, 임상, 진단, [키워드] adjusted Adult patient age bamlanivimab cardiovascular diseases Casirivimab chronic clinical clinical outcomes Comorbidities Comorbidity coronavirus disease COVID-19 Factor female groups hazard ratio high-risk patient High-risk patients Hospitalization identify immunocompromised status kidney likelihood Mild moderate monoclonal antibody monoclonal antibody treatment multiple comorbidities no significant difference outcome outcomes Patient selected the median therapy Treatment [DOI] 10.1093/infdis/jiab377 PMC 바로가기 [Article Type] Observational Study
Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient childIRF9 결핍 아동에서 SARS-CoV-2의 단일 클론 항체 매개 중화Case Reports Published on 2021-10-262022-09-10 Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 변종, 진단, [키워드] antibody Antiviral autoantibodies autoantibody Blood blood type Casirivimab caused children clinical manifestation clinical manifestations component Course COVID-19 COVID-19 pneumonia Critical deficiency expression girl high risk IFN IFN-stimulated gene IFN-stimulated genes IFN-α2 IFNs Imdevimab Immunity Infection Influenza influenza pneumonia inherited deficiency inherited primary immunodeficiency interferon interferons IRF9 lack leukocyte leukocytes life-threatening monoclonal antibodies monoclonal antibody nasal neutralization Neutralizing neutralizing monoclonal antibody overcome Patient peaked Pneumonia prevented reported respiratory respiratory tract infection response risk RNA-Seq SARS-CoV-2 SARS-CoV-2 neutralization SARS-CoV-2 virus secretion selected Significance transcription factor type I type I and III interferons type I IFNs type I interferon Type III IFN upper respiratory tract upper respiratory tract infection Viremia virus [DOI] 10.1073/pnas.2114390118 PMC 바로가기 [Article Type] Case Reports
SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients신장 이식 환자의 코로나19 치료를 위한 SARS-CoV-2 중화 단일클론 항체Article Published on 2021-10-202022-09-11 Journal: Kidney360 [Category] MERS, SARS, 진단, 치료기술, [키워드] ACE2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 anti-SARS-CoV-2 IgG bamlanivimab blocking activity Casirivimab Clinical outcome coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease death demonstrated detectable diagnosed diagnosed with COVID-19 disease Emergency use authorization enzyme highest Hospitalization Imdevimab Immunosuppression Infection Intervention kidney kidney transplant kidney transplant recipient kidney transplant recipients mAb mAbs Mild mild to moderate Mild to moderate COVID-19 mild to moderate COVID-19 disease mild to moderate disease Moderate COVID-19 moderate disease monoclonal monoclonal antibodies morbidity Mortality natural immunity Neutralizing Patient patients treated performed Prevent progression receive receptor recipient reduction required Retrospective analysis SARS-CoV-2 serology testing severe disease the United State Transplant transplantation treated Treatment United States with COVID-19 [DOI] 10.34067/KID.0005732021 PMC 바로가기 [Article Type] Article